IDH1 and acute myeloid leukemia: For example, studies have shown that for acute myeloid leukaemia (AML) patients with IDH1 mutation, the use of drugs targeting the inhibition of mutant IDH1 alone may cause patients to be insensitive to drugs, mainly due to the inhibition of mutant IDH1, which could also cause the improvement of glycolysis [266,267].